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Abstract
Background: Tacrolimus and cyclosporine, both calcineurin inhibitors, can cause neurological
side effects. While mild symptoms such as tremor are well recognised, severe complications
including seizures and encephalopathy are poorly documented following renal transplantation.
Case presentation: We report a 42 year old man who received a cadaver renal transplant. He
received tacrolimus and prednisolone. The course was uneventful for 6 weeks when he became
intermittently confused, with unsteady gait and slurred speech. Following a grand mal convulsion
he was admitted. He had no focal neurological signs, cerebrospinal fluid was normal;
electroencephalogram was consistent with temporal lobe partial epilepsy. The magnetic resonance
imaging of brain showed widespread changes with multiple areas of low signal intensity in brain
stem and cerebral hemispheres. He was readmitted 3 weeks later after further fits, despite anti-
convulsant therapy. He was psychotic with visual hallucinations, and rapidly became obtunded.
Although his tacrolimus blood concentration had been kept in the normal range, his symptoms
improved dramatically when the tacrolimus was stopped.
Conclusion: Severe central nervous system toxicity from calcineurin inhibitors has been rarely
reported in renal transplantation and we found only one report of tacrolimus-induced toxicity in
an adult. We believe the condition is frequently undiagnosed. It is a very important diagnosis not
to miss as the remedy is simple and failure may result in unnecessary brain biopsy, as well as
irreversible injury.
Background
Neurological complications of tacrolimus are usually
mild (tremors, paraesthiae and myalgia), but can be
severe with encephalopathy, seizures and coma. Severe
complications have been more frequently reported fol-
lowing liver and lung than with renal transplantation [1-
4], and typically occur with tacrolimus concentrations
consistently above the therapeutic range of 15 ng/ml. We
report the case of progressive neurological deterioration
in a renal allograft recipient who suffered convulsions,
intermittent confusion and finally mental obtundation.
Severe central nervous system (CNS) toxicity from cal-
cineurin inhibitors has been rarely reported in renal trans-
plantation [2,5] and we found only one report of
tacrolimus in an adult[6]. We believe the condition is fre-
quently undiagnosed, and in our case the diagnosis was
not considered for 2 months after onset of symptoms.
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Case report
A 42 years old man of mixed race with an African father
had originally presented with severe hypertension and
renal failure. Renal biopsy showed severe vascular pathol-
ogy but no primary glomerular disease. He underwent a
cadaver renal transplant (111 mis-match) in July 2002
and received tacrolimus and prednisolone. The kidney
functioned immediately. On day 8 (d8) with a plasma cre-
atinine that had not fallen below 180 µmol/l and tac-
rolimus concentration consistently 15 ng/ml (target
concentration 10–15 ng/ml), he had a renal biopsy that
showed acute rejection (Banff IIa). He received intrave-
nous methylprednisolone and Cellcept 500 mg bd was
added. The creatinine fell to125 µmol/l.
Eight weeks after transplantation (d59) he was admitted
to another hospital following a road traffic accident.
Whilst driving he had experienced sudden onset of drow-
siness with headache and numbness in his fingers and
toes. He temporarily lost consciousness and collided with
another vehicle. Computed tomography (CT) scan of his
head showed no abnormality and he was discharged
home the following day. The following week he was read-
mitted (d66). He had a month history of persistent frontal
headache, relieved by simple analgesic. He was intermit-
tently confused and unable to recognize members of his
family. This was associated with unsteady gait and slurred
speech. During these episodes he appeared withdrawn
and somewhat blank. Episodes lasted 1–8 hours. He had
had one grand mal convulsion witnessed at home. There
was no previous history or family history of neurological
disease. On admission, he was afebrile with blood pres-
sure of 120/75. He had no focal neurological deficit and
no meningism. Cerebrospinal fluid (CSF) examination
was normal: microscopy, Gram and Zeihl-Nielson stain,
cytology, virology, glucose, protein, cultures and India-
ink for cryptococcus were unremarkable. Blood cultures,
blood count, Chest and skull X-ray were normal. Electro-
encephalogram (EEG) revealed sharpening and spikes
independently in both temporal lobes consistent with
temporal lobe partial epilepsy. The magnetic resonance
imaging (MRI) of brain showed multiple areas of low sig-
nal intensity (T1-weighted FLASH) in the pons, medulla
oblongata, basal ganglia and also in the cerebral hemi-
spheres (figure 1). These lesions were reported as 'consist-
ent with small vessel ischemia secondary to hypertension'.
The diagnosis of partial epilepsy was made and he was
started on lamotrigine. His renal function remained sta-
ble. Magnesium was consistently at the lower limit of nor-
mal range 0.6 mmol/l (normal range 0.6 – 1.1 mmol/l),
cholesterol 4.5 mmol/l (2.3 – 5.2 mmol/l). The tac-
rolimus level was kept within range 8–15 ng/dl.
He was readmitted three weeks later (d113) having had
further fits. He was agitated, psychotic with visual halluci-
nations. No focal neurology was found and he rapidly
became obtunded with a Glasgow coma score of 6–8/15.
Repeat CT and MRI were unchanged. Lumbar puncture
revealed high open pressure and raised protein 1.3 g/l but
CSF analysis was otherwise normal. Repeat EEG was con-
sisted with complex partial status epileptics with "fre-
quent frontal notched theta activity". He was treated with
antibiotic and antifungal agents and phenytoin infusion.
There was no improvement in his condition and a diagno-
sis of tacrolimus-induced neurotoxicity was made (tac-
rolimus 10 ng/ml). Tacrolimus was switched to
cyclosporine. Over the next few days he showed rapid and
progressive improvement. He recovered fully and was dis-
charge home. He has had no further seizure activity nor
neurological symptoms since tacrolimus had been
stopped. He continues to do well. A MRI scan performed
in 2004 no longer showed the earlier lesions.
Conclusion
Severe calcineurin inhibitor-induced CNS toxicity is asso-
ciated with a leucoencephalopathy [7]. Neuro-radiologi-
cal abnormalities are most commonly seen in the parietal-
occipital region and appear as multifocal low attenuation
of white matter on CT scan with corresponding hyper-
intense lesions on MRI (T2-weighted)[3]. The changes
may be very subtle[8,9]. It has been suggested that the less
frequent grey matter pathology can be visualised better
using MRI with fluid-attenuated inversion recovery
MRI Brain Figure 1
MRI Brain. There are multiple areas of low signal intensity 
in the pons, medulla oblongata, basal ganglia and also in the 
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(FLAIR)[10]. These changes, however, are not specific. Six-
teen patients with cyclosporine neurotoxicity investigated
with MRI scans had findings identical to those reported in
hypertensive encephalopathy and in 14 of 16 the symp-
toms improved after Bp became normal[11].
CSF analysis in calcineurin inhibitor-induced CNS toxic-
ity is either normal or there may be a slight elevation of
protein concentration as in our case[12]. EEG may be
non-specifically encephalopathic with diffuse slowing or
may shown frank epileptic discharges as in the present
case[13].
Cases generally occur early when blood levels of tac-
rolimus or cyclosporine are high, but can occur with nor-
mal levels. A review of 50 reported cases found a median
time to onset of 28 days, with 82% of cases occurring
within 90 days [2]. Typically symptoms improved
promptly when the dose was reduced or the drug stopped,
but recovery can be incomplete [1,14,15]. The onset can
be late, severe and irreversible [1,6].
From the review of 50 cases by Singh and colleagues[2],
seizures 74%, altered mental status 50%, and visual
abnormalities 28% were the most frequently presenting
features. Ten percent of the patients had fever with no doc-
umented source of infection[2].
Severe neurotoxicity in renal patients is usually multifac-
torial, with patients systemically unwell, uraemic and
receiving combinations of potentially neurotoxic drugs.
With cyclosporine leucoencephalopathy other contribut-
ing factors have been reported. Hypocholesterolae-
mia[13] and hypomagnesaemia[16] have been
implicated, but were not present in our case; similarly,
onset has often been associated with high blood pressure
and fluid overload [11], which were also not features of
this case. Initially it was assumed that the encephalopathy
had an ischaemic basis, but more recently the similarity to
mitochondrial encephalopathy has been described and
investigated [7].
In our case the tacrolimus levels were often in the high
normal range, particularly in the second month of his ill-
ness which was the fourth transplant month. We would
recommend that tacrolimus levels are kept below 10 ng/
ml after the second transplant month in straightforward
transplants. Calcineurin inhibitor-induced CNS toxicity is
a very important diagnosis not to miss as the remedy is
simple and failure may result in unnecessary brain biopsy,
as well as irreversible injury.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
All the authors were involved in the clinical management
of the case and the writing of the report.
Acknowledgements
Written consent was obtained from the patient for publication of study.
References
1. Fruhauf NR, Koeppen DS, Saner FH, Egelhof DT, Stavrou G, Nadalin
S, Broelsch CE: Late onset of tacrolimus-related posterior leu-
koencephalopathy after living donor liver transplantation.
Liver Transpl 2003, 9:983-985.
2. Singh N, Bonham A, Fukui M: Immunosuppressive-associated
leukoencephalopathy in organ transplant recipients.  Trans-
plantation 2000, 69:467-472.
3. Appignani BA, Bhadelia RA, Blacklow SC, Wang AK, Roland SF, Free-
man RBJ: Neuroimaging findings in patients on immunosup-
pressive therapy: experience with tacrolimus toxicity.  AJR Am
J Roentgenol 1996, 166:683-688.
4. de Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RA: Central
nervous system toxicity after liver transplantation. The role
of cyclosporine and cholesterol.  N Engl J Med 1987,
317:861-866.
5. Parvex P, Pinsk M, Bell LE, O'Gorman AM, Patenaude YG, Gupta IR:
Reversible encephalopathy associated with tacrolimus in
pediatric renal transplants.  Pediatr Nephrol 2001, 16:537-542.
6. Grimbert P, Azema C, Pastural M, Dhamane D, Remy P, Salomon L,
Schortgen F, Baron C, Lang P: Tacrolimus (FK506)-induced
severe and late encephalopathy in a renal transplant recipi-
ent.  Nephrol Dial Transplant 1999, 14:2489-2491.
7. Serkova NJ, Christians U, Benet LZ: Biochemical mechanisms of
cyclosporine neurotoxicity.  Mol Interv 2004, 4:97-107.
8. Jansen O, Krieger D, Krieger S, Sartor K: Cortical hyperintensity
on proton density-weighted images: An MR sign of
cyclosporine-related encephalopathy.  AJNR Am J Neuroradiol
1996, 17:337-344.
9. Zimmer WE, Hourihane JM, Wang HZ, Schriber JR: The effect of
human leukocyte antigen disparity on cyclosporine neuro-
toxicity after allogeneic bone marrow transplantation.  AJNR
Am J Neuroradiol 1998, 19:601-608.
10. Casey SO, Sampaio RC, Michel E, Truwit CL: Posterior reversible
encephalopathy syndrome: utility of fluid-attenuated inver-
sion recovery MR imaging in the detection of cortical and
subcortical lesions.  AJNR Am J Neuroradiol 2000, 21:1199-1206.
11. Schwartz RB, Bravo SM, Klufas RA, Hsu L, Barnes PD, Robson CD,
Antin JH: Cyclosporine neurotoxicity and its relationship to
hypertensive encephalopathy: CT and MR findings in 16
cases.  AJR Am J Roentgenol 1995, 165:627-631.
12. Small SL, Fukui MB, Bramblett GT, Eidelman BH: Immunosuppres-
sion-induced leukoencephalopathy from tacrolimus
(FK506).  Ann Neurol 1996, 40:575-580.
13. Gleeson JG, duPlessis AJ, Barnes PD, Riviello JJJ: Cyclosporin A
acute encephalopathy and seizure syndrome in childhood:
clinical features and risk of seizure recurrence.  J Child Neurol
1998, 13:336-344.
14. Torocsik HV, Curless RG, Post J, Tzakis AG, Pearse L: FK506-
induced leukoencephalopathy in children with organ trans-
plants.  Neurology 1999, 52:1497-1500.
15. Misawa A, Takeuchi Y, Hibi S, Todo S, Imashuku S, Sawada T: FK506-
induced intractable leukoencephalopathy following alloge-
neic bone marrow transplantation.  Bone Marrow Transplant
2000, 25:331-334.
16. Thompson CB, June CH, Sullivan KM, Thomas ED: Association
between cyclosporin neurotoxicity and hypomagnesaemia.
Lancet 1984, 2:1116-1120.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2369/7/7/prepub